BIAF

bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

Wall Street analysts forecast BIAF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIAF is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

bioAffinity Technologies Inc revenue for the last quarter amounts to 1.45M USD, decreased -38.48 % YoY.

bioAffinity Technologies Inc. EPS for the last quarter amounts to -4.74 USD, decreased -2.07 % YoY.

bioAffinity Technologies Inc (BIAF) has 57 emplpoyees as of December 15 2025.

Today BIAF has the market capitalization of 6.79M USD.